# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and enginee...
HC Wainwright & Co. analyst Joseph Pantginis reiterates BiomX (AMEX:PHGE) with a Buy and maintains $2 price target.
BiomX (AMEX:PHGE) reported quarterly losses of $(0.07) per share. This is a 41.67 percent increase over losses of $(0.12) per s...